568 related articles for article (PubMed ID: 28463241)
1. Serum kynurenic acid is reduced in affective psychosis.
Wurfel BE; Drevets WC; Bliss SA; McMillin JR; Suzuki H; Ford BN; Morris HM; Teague TK; Dantzer R; Savitz JB
Transl Psychiatry; 2017 May; 7(5):e1115. PubMed ID: 28463241
[TBL] [Abstract][Full Text] [Related]
2. Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder.
Meier TB; Drevets WC; Wurfel BE; Ford BN; Morris HM; Victor TA; Bodurka J; Teague TK; Dantzer R; Savitz J
Brain Behav Immun; 2016 Mar; 53():39-48. PubMed ID: 26546831
[TBL] [Abstract][Full Text] [Related]
3. Kynurenine pathway metabolites are associated with hippocampal activity during autobiographical memory recall in patients with depression.
Young KD; Drevets WC; Dantzer R; Teague TK; Bodurka J; Savitz J
Brain Behav Immun; 2016 Aug; 56():335-42. PubMed ID: 27091600
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder.
Savitz J; Dantzer R; Wurfel BE; Victor TA; Ford BN; Bodurka J; Bellgowan PS; Teague TK; Drevets WC
Psychoneuroendocrinology; 2015 Feb; 52():200-11. PubMed ID: 25486577
[TBL] [Abstract][Full Text] [Related]
5. Activation of the kynurenine pathway is associated with striatal volume in major depressive disorder.
Savitz J; Dantzer R; Meier TB; Wurfel BE; Victor TA; McIntosh SA; Ford BN; Morris HM; Bodurka J; Teague TK; Drevets WC
Psychoneuroendocrinology; 2015 Dec; 62():54-8. PubMed ID: 26232650
[TBL] [Abstract][Full Text] [Related]
6. Kynurenic acid is reduced in females and oral contraceptive users: Implications for depression.
Meier TB; Drevets WC; Teague TK; Wurfel BE; Mueller SC; Bodurka J; Dantzer R; Savitz J
Brain Behav Immun; 2018 Jan; 67():59-64. PubMed ID: 28867283
[TBL] [Abstract][Full Text] [Related]
7. Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder.
Savitz J; Drevets WC; Wurfel BE; Ford BN; Bellgowan PS; Victor TA; Bodurka J; Teague TK; Dantzer R
Brain Behav Immun; 2015 May; 46():55-9. PubMed ID: 25686798
[TBL] [Abstract][Full Text] [Related]
8. Sleep disturbance and kynurenine metabolism in depression.
Cho HJ; Savitz J; Dantzer R; Teague TK; Drevets WC; Irwin MR
J Psychosom Res; 2017 Aug; 99():1-7. PubMed ID: 28712413
[TBL] [Abstract][Full Text] [Related]
9. C-Reactive protein and the kynurenic acid to quinolinic acid ratio are independently associated with white matter integrity in major depressive disorder.
Zheng H; Teague TK; Yeh FC; Burrows K; Figueroa-Hall LK; Aupperle RL; Khalsa SS; Paulus MP; Savitz J
Brain Behav Immun; 2022 Oct; 105():180-189. PubMed ID: 35853557
[TBL] [Abstract][Full Text] [Related]
10. The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression.
Lavebratt C; Olsson S; Backlund L; Frisén L; Sellgren C; Priebe L; Nikamo P; Träskman-Bendz L; Cichon S; Vawter MP; Osby U; Engberg G; Landén M; Erhardt S; Schalling M
Mol Psychiatry; 2014 Mar; 19(3):334-41. PubMed ID: 23459468
[TBL] [Abstract][Full Text] [Related]
11. The kynurenine pathway in schizophrenia and bipolar disorder.
Erhardt S; Schwieler L; Imbeault S; Engberg G
Neuropharmacology; 2017 Jan; 112(Pt B):297-306. PubMed ID: 27245499
[TBL] [Abstract][Full Text] [Related]
12. Role of Kynurenine Metabolism Pathway Activation in Major Depressive Disorders.
Savitz J
Curr Top Behav Neurosci; 2017; 31():249-267. PubMed ID: 27221627
[TBL] [Abstract][Full Text] [Related]
13. A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality.
Bay-Richter C; Linderholm KR; Lim CK; Samuelsson M; Träskman-Bendz L; Guillemin GJ; Erhardt S; Brundin L
Brain Behav Immun; 2015 Jan; 43():110-7. PubMed ID: 25124710
[TBL] [Abstract][Full Text] [Related]
14. Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia.
Beggiato S; Notarangelo FM; Sathyasaikumar KV; Giorgini F; Schwarcz R
J Psychopharmacol; 2018 Nov; 32(11):1223-1232. PubMed ID: 30354938
[TBL] [Abstract][Full Text] [Related]
15. Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine.
Johansson AS; Owe-Larsson B; Asp L; Kocki T; Adler M; Hetta J; Gardner R; Lundkvist GB; Urbanska EM; Karlsson H
J Psychiatr Res; 2013 Nov; 47(11):1815-23. PubMed ID: 24012176
[TBL] [Abstract][Full Text] [Related]
16. Kynurenine 3-Monooxygenase Activity in Human Primary Neurons and Effect on Cellular Bioenergetics Identifies New Neurotoxic Mechanisms.
Castellano-Gonzalez G; Jacobs KR; Don E; Cole NJ; Adams S; Lim CK; Lovejoy DB; Guillemin GJ
Neurotox Res; 2019 Apr; 35(3):530-541. PubMed ID: 30666558
[TBL] [Abstract][Full Text] [Related]
17. Increased breakdown of kynurenine towards its neurotoxic branch in bipolar disorder.
Birner A; Platzer M; Bengesser SA; Dalkner N; Fellendorf FT; Queissner R; Pilz R; Rauch P; Maget A; Hamm C; Herzog-Eberhard S; Mangge H; Fuchs D; Moll N; Zelzer S; Schütze G; Schwarz M; Reininghaus B; Kapfhammer HP; Reininghaus EZ
PLoS One; 2017; 12(2):e0172699. PubMed ID: 28241062
[TBL] [Abstract][Full Text] [Related]
18. Kynurenine pathway in depression: A systematic review and meta-analysis.
Ogyu K; Kubo K; Noda Y; Iwata Y; Tsugawa S; Omura Y; Wada M; Tarumi R; Plitman E; Moriguchi S; Miyazaki T; Uchida H; Graff-Guerrero A; Mimura M; Nakajima S
Neurosci Biobehav Rev; 2018 Jul; 90():16-25. PubMed ID: 29608993
[TBL] [Abstract][Full Text] [Related]
19. Kynurenine 3-hydroxylase inhibition in rats: effects on extracellular kynurenic acid concentration and N-methyl-D-aspartate-induced depolarisation in the striatum.
Urenjak J; Obrenovitch TP
J Neurochem; 2000 Dec; 75(6):2427-33. PubMed ID: 11080194
[TBL] [Abstract][Full Text] [Related]
20. Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls.
Holtze M; Saetre P; Engberg G; Schwieler L; Werge T; Andreassen OA; Hall H; Terenius L; Agartz I; Jönsson EG; Schalling M; Erhardt S
J Psychiatry Neurosci; 2012 Jan; 37(1):53-7. PubMed ID: 21693093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
